Longâ€term followâ€up results of the Pacing to Avoid C trial

European Journal of Heart Failure 16, 1016-1025

DOI: 10.1002/ejhf.157

Citation Report

#	Article	IF	CITATIONS
1	Deterioration of left ventricular systolic function in extended Pacing to Avoid Cardiac Enlargement (PACE) trial: the predictive value of early systolic dyssynchrony. Europace, 2015, 17, ii47-ii53.	0.7	5
2	Cardiac Resynchronization Therapy Is Appropriate for All Patients Requiring Chronic Right Ventricular Pacing. Cardiac Electrophysiology Clinics, 2015, 7, 433-444.	0.7	3
3	Should All Patients With Heart Block Receive Biventricular Pacing?. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 722-729.	2.1	7
4	Biventricular pacing for bradycardia: Are we there yet?. Journal of Electrocardiology, 2015, 48, 236-240.	0.4	O
5	The changing landscape of cardiac pacing. Herzschrittmachertherapie Und Elektrophysiologie, 2015, 26, 32-38.	0.3	5
6	The Role of Biventricular Pacing in the Prevention and Therapy of Pacemakerâ€Induced Cardiomyopathy. Annals of Noninvasive Electrocardiology, 2015, 20, 224-239.	0.5	13
7	Rationale and design of the BUDAPEST-CRT Upgrade Study: a prospective, randomized, multicentre clinical trial. Europace, 2017, 19, euw193.	0.7	17
8	Outcomes Related to First-Degree Atrioventricular Block and Therapeutic Implications in Patients With Heart Failure. JACC: Clinical Electrophysiology, 2016, 2, 181-192.	1.3	29
9	Left ventricular dysfunction is related to the presence and extent of a septal flash in patients with right ventricular pacing. Europace, 2017, 19, euw020.	0.7	19
	6		
10	Pacing for Sinus Node Disease., 2017,, 375-398.		1
10		0.9	47
	Pacing for Sinus Node Disease., 2017,, 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing.	0.9	
11	Pacing for Sinus Node Disease. , 2017, , 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . Longâ€term administration of pyridostigmine attenuates pressure overloadâ€induced cardiac hypertrophy		47
11	Pacing for Sinus Node Disease. , 2017, , 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . Longâ€term administration of pyridostigmine attenuates pressure overloadâ€induced cardiac hypertrophy by inhibiting calcineurin signalling. Journal of Cellular and Molecular Medicine, 2017, 21, 2106-2116. Risk Stratification of Future Left Ventricular Dysfunction for Patients with Indications for Right	1.6	47 17
11 12 13	Pacing for Sinus Node Disease., 2017, , 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, . Longâ€term administration of pyridostigmine attenuates pressure overloadâ€induced cardiac hypertrophy by inhibiting calcineurin signalling. Journal of Cellular and Molecular Medicine, 2017, 21, 2106-2116. Risk Stratification of Future Left Ventricular Dysfunction for Patients with Indications for Right Ventricular Pacing due to Bradycardia. International Heart Journal, 2017, 58, 724-730. Cardiac Resynchronization Therapy in Patients with Ebstein's Anomaly. International Heart Journal,	1.6 0.5	47 17 9
11 12 13	Pacing for Sinus Node Disease., 2017,, 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. Circulation: Cardiovascular Quality and Outcomes, 2017, 10,. Longâ€term administration of pyridostigmine attenuates pressure overloadâ€induced cardiac hypertrophy by inhibiting calcineurin signalling. Journal of Cellular and Molecular Medicine, 2017, 21, 2106-2116. Risk Stratification of Future Left Ventricular Dysfunction for Patients with Indications for Right Ventricular Pacing due to Bradycardia. International Heart Journal, 2017, 58, 724-730. Cardiac Resynchronization Therapy in Patients with Ebstein's Anomaly. International Heart Journal, 2017, 58, 816-819. Chronic Right Ventricular Pacing in the Heart Failure Population. Current Heart Failure Reports, 2018,	1.6 0.5	47 17 9
11 12 13 14	Pacing for Sinus Node Disease., 2017,, 375-398. Incidence and Time Course for Developing Heart Failure With High-Burden Right Ventricular Pacing. Circulation: Cardiovascular Quality and Outcomes, 2017, 10,. Longâcterm administration of pyridostigmine attenuates pressure overloadâcinduced cardiac hypertrophy by inhibiting calcineurin signalling. Journal of Cellular and Molecular Medicine, 2017, 21, 2106-2116. Risk Stratification of Future Left Ventricular Dysfunction for Patients with Indications for Right Ventricular Pacing due to Bradycardia. International Heart Journal, 2017, 58, 724-730. Cardiac Resynchronization Therapy in Patients with Ebstein's Anomaly. International Heart Journal, 2017, 58, 816-819. Chronic Right Ventricular Pacing in the Heart Failure Population. Current Heart Failure Reports, 2018, 15, 61-69.	1.6 0.5 0.5	47 17 9 4 16

#	Article	IF	CITATIONS
19	Pacing-induced cardiomyopathy: just the tip of the iceberg?. European Heart Journal, 2019, 40, 3649-3650.	1.0	7
20	Impact of physiologic pacing versus right ventricular pacing among patients with left ventricular ejectionÂfraction greater than 35%: AÂsystematic review for the 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. Heart Rhythm, 2019. 16. e280-e298.	0.3	11
21	Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular EjectionÂFraction Greater Than 35%: AASystematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. Journal of	1.2	30
22	the American College of Cardiology, 2019, 74, 988-1008. Impact of Physiologic Pacing Versus Right Ventricular Pacing Among Patients With Left Ventricular Ejection Fraction Greater Than 35%: A Systematic Review for the 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice	1.6	21
23	Early Change in Global Longitudinal Strain is an Independent Predictor of Left Ventricular Adverse Remodelling in Patients With Right Ventricular Apical Pacing. Heart Lung and Circulation, 2019, 28, 1780-1787.	0.2	6
24	Outcome in patients undergoing upgrade to cardiac resynchronization therapy: predictors of outcome after upgrade to CRT. Heart and Vessels, 2020, 35, 104-109.	0.5	4
25	Pacing induced cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2020, 31, 286-292.	0.8	61
26	Right ventricular pacing-induced cardiomyopathy: Is there a role for blood biomarkers?. Hellenic Journal of Cardiology, 2021, 62, 370-371.	0.4	0
27	Right ventricular pacing-induced cardiomyopathy: Is there a role for blood biomarkers?. Hellenic Journal of Cardiology, 2020, 61, 279-280.	0.4	1
28	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
29	Effects of long-term right ventricular apex pacing on left ventricular dyssynchrony, morphology and systolic function. International Journal of Cardiology, 2021, 331, 91-99.	0.8	1
30	Clinical Outcomes in Patients With Left Bundle Branch Area Pacing vs. Right Ventricular Pacing for Atrioventricular Block. Frontiers in Cardiovascular Medicine, 2021, 8, 685253.	1.1	21
31	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2021, 42, 3427-3520.	1.0	899
32	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace, 2022, 24, 71-164.	0.7	370
33	Pacemaker Induced Cardiomyopathy: An Overview of Current Literature. Current Cardiology Reviews, 2022, 18, .	0.6	5
34	Pacing of Specialized Conduction System. Cardiac Electrophysiology Clinics, 2021, 13, 755-784.	0.7	4
35	Cardiac Resynchronisation Therapy and Heart Failure: Persepctive from 5P Medicine. Cardiac Failure Review, 2015, 1, 35.	1.2	5
36	The short term influence of right ventricular pacing burden on echocardiographic and spiroergometric parameters in patients with preserved left ventricular ejection fraction. BMC Cardiovascular Disorders, 2022, 22, 23.	0.7	O

#	Article	IF	CITATIONS
38	Incidence and predictors of pacemaker-induced cardiomyopathy with right ventricular pacing: a systematic review. Expert Review of Cardiovascular Therapy, 2022, , 1-7.	0.6	3
39	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Translation of the document prepared by the Czech Society of Cardiology. Cor Et Vasa, 2022, 64, 7-86.	0.1	1
40	Pacing-induced cardiomyopathy: A systematic review and meta-analysis of definition, prevalence, risk factors, and management. Heart Rhythm, 2023, 20, 282-290.	0.3	22
41	Cardiomyopathy Associated with Right Ventricular Apical Pacing-Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 6889.	1.0	3
42	Diretriz Brasileira de Dispositivos CardÃacos Eletrônicos Implantáveis – 2023. Arquivos Brasileiros De Cardiologia, 2023, 120, .	0.3	1
43	A Case Report of Pacemaker-Induced Cardiomyopathy in a Patient With Post-atrioventricular Node Ablation for Atrial Fibrillation. Cureus, 2023, , .	0.2	O
44	Long-term follow-up of selective and non-selective His bundle pacing leads in patients with atrioventricular block. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 1849-1857.	0.6	0
45	Left bundle branch block – dilated cardiomyopathy – heart failure: common links in the closed pathogenetic chain. Kardiologiya, 2023, 63, 68-76.	0.3	1
46	Pacing induced cardiomyopathy: recognition and management. Heart, 2023, 109, 1407-1415.	1.2	7